Premier Alternatives

Nacuity Pharmaceuticals

Fort Worth, TX · Founded 2017 · Privately Held (backing)

Operator of a biotechnology company intended to offer treatments for retinitis pigmentosa and other ophthalmological disorders. Nacuity Pharmaceuticals is based in Fort Worth, TX and was founded in 2017. Its last reported valuation was $52 million in Jun 2022. It has raised $40.6 million across 4 recorded rounds; the latest was an $8.4 million early-stage round in Dec 2025.

Last reported valuation
$52.0M
Oct 2026
Priced at
—
Total raised
$40.6M
Last round
Early Stage VC
Dec 2025

Nacuity Pharmaceuticals key facts

as of Oct 2026
  • Operator of a biotechnology company intended to offer treatments for retinitis pigmentosa and other ophthalmological disorders.
  • Nacuity Pharmaceuticals is valued at approximately $52.0M as of Oct 2026 (last reported valuation).
  • It has raised $40.6M across 4 recorded rounds; the latest was Early Stage VC ($8.4M) in Dec 2025.
  • Notable investors include Foundation Fighting Blindness-National Neurovision Research Institute, HSC Next, Johns Hopkins Technology Ventures, Retinal Degeneration Fund, Tarnagulla Ventures.
  • Nacuity Pharmaceuticals has filed 5 Form Ds with the SEC since 2016, most recently Jan 2022 ($11.6M sold to 144 investors).
  • Status: Privately Held (backing).
Last reported valuation
LOW confidence
$52.0M

Nacuity Pharmaceuticals's last reported valuation, Jun 2022. Nothing priced has surfaced since.

set by last reported valuationas of Oct 2026question about this number?
Free account
More of Nacuity Pharmaceuticals with a free account
  • ·Watch Nacuity Pharmaceuticals: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Nacuity Pharmaceuticals funding rounds

4 rounds
Dec 2025Early Stage VC$8.4MSEC filing▮
Mar 2021Early Stage VC$11.6MSEC filing▮
Jun 2017Early Stage VC$9.2MSEC filing▮
Nov 2016Seed Round$2.0MSEC filing▮
Full funding history →

Nacuity Pharmaceuticals valuation

Nacuity Pharmaceuticals's last reported valuation was $52 million in Jun 2022. No priced round, secondary trade or fund mark has surfaced since.

How much has Nacuity Pharmaceuticals raised?

Nacuity Pharmaceuticals has raised $40.6 million across 4 recorded rounds since 2016. The largest was a $9.2 million early-stage round in Jun 2017; the most recent was an $8.4 million early-stage round in Dec 2025.

Nacuity Pharmaceuticals has filed 5 Form Ds with the SEC since 2016, most recently in Jan 2022 ($11.6 million sold to 144 investors).

Nacuity Pharmaceuticals investors

5 investors are on record for Nacuity Pharmaceuticals, including Foundation Fighting Blindness-National Neurovision Research Institute, HSC Next, Johns Hopkins Technology Ventures and Retinal Degeneration Fund. The early-stage round in Dec 2025 drew 98 investors.

About Nacuity Pharmaceuticals

Operator of a biotechnology company intended to offer treatments for retinitis pigmentosa and other ophthalmological disorders. The company offers drug candidates focused on treating ocular oxidative stress and other ocular diseases, enabling healthcare professionals to help and treat patients suffering from such disorders.

Sector
Healthcare
HQ
Fort Worth, TX, United States
Founded
2017
Employees
6
Ownership
Privately Held (backing)

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.